NewAmsterdam Pharma Co N.V.
NAMS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001936258
In the last 90 days, NewAmsterdam Pharma Co N.V. insiders filed 1 open-market purchase and 3 sales; 194 institutions reported holding it in 13F filings for Q2 2026, worth $4.13B in total; 3 superinvestors hold it, including Viking Global Investors and Maverick Capital.
Other share classesNAMSW
Key figures
- Market capClose on Nov 13, 2026
- $2.42B
- Insider buysLast 90 days, $226.5K in total
- 1
- Insider sellsLast 90 days, $4.66M in total
- 3
- 13F holdersQ2 2026, +26 vs. previous quarter
- 194
- 13F valueReported value at the end of Q2 2026
- $4.13B
- Superinvestors holdingAt the end of Q2 2026
- 3
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $22.5M
- −50.6% year over year
- Net income, FY2025
- -$203.8M
- No comparable prior period
- Free cash flow, FY2025
- -$148.0M
- No comparable prior period
- Revenue, Q3 FY2026
- $19.2M
- +5,406.9% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $203.8M (905.7% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 12.0M
- Shares sold short
- Change
- −2.10M
- −14.9% vs. previous
- Days to cover
- 8.32
- At average daily volume
Superinvestors holding NAMS, Q2 2026
Go to the superinvestors tab3 superinvestors report holding NewAmsterdam Pharma Co N.V. on Form 13F. Percentages are the stock's share of each portfolio.
Viking Global Investors
Andreas Halvorsen
0.4%
NewAmsterdam Pharma Co N.V.'s share of the portfolio
- Shares
- 4,203,567
- Value
- $142.5M
Maverick Capital
Lee Ainslie
1.0%
NewAmsterdam Pharma Co N.V.'s share of the portfolio
- Shares
- 3,267,802
- Value
- $110.7M
| Superinvestor | Weight | Value |
|---|---|---|
| Duquesne Family Office | 2.4% | $104.0M |
Latest insider trades
See all insider tradesOpen-market purchases and sales by NewAmsterdam Pharma Co N.V. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 2, 2026 (view filing)4:30 PM ET | Sep 30 | 2 days | Kastelein Johannes Jacob PieterChief Scientific Officer | SSale | −50.2K | $25.03 | −$1.26M | −42.0%69.3K after | 10b5-1 |
| Sep 15, 2026 (view filing)4:30 PM ET | Sep 14 | 1 day | Davidson Michael H.Chief Executive Officer | PPurchase | +10.0K | $22.65 | +$226.5K | +1.3%792.9K after | |
| Sep 9, 2026 (view filing)4:30 PM ET | Sep 4 | 5 days | Smither John WDirector | SSale | −1.60K | $25.32 | −$40.5K | −15.4%8.76K after | |
| Aug 25, 2026 (view filing)4:30 PM ET | Aug 24 | 1 day | Kastelein Johannes Jacob PieterChief Scientific Officer | SSale | −125.0K | $26.91 | −$3.36M | −64.3%69.3K after | 10b5-1 |
| Jul 22, 2026 (view filing)4:05 PM ET | Jul 20 | 2 days | Kooij Louise FrederikaChief Accounting Officer | SSale | −105.0K | $30.34 | −$3.19M | −81.2%24.4K after | 3 lots10b5-1 |
| Jun 24, 2026 (view filing) | Jun 22 | 2 days | Kooij Louise FrederikaChief Accounting Officer | SSale | −40.0K | $30.20 | −$1.21M | −62.2%24.4K after | 2 lots10b5-1 |
| May 27, 2026 (view filing) | May 26 | 1 day | Kooij Louise FrederikaChief Accounting Officer | SSale | −65.0K | $35.69 | −$2.32M | −72.7%24.4K after | 10b5-1 |
| Mar 12, 2026 (view filing) | Mar 11 | 1 day | Lange Louis GDirector | SSale | −44.6K | $30.42 | −$1.36M | −81.2%10.4K after | 2 lots |
| Mar 10, 2026 (view filing) | Mar 6 | 4 days | Lange Louis GDirector | SSale | −28.2K | $29.41 | −$829.0K | −100.0%0 after | |
| Mar 9, 2026 (view filing) | Mar 5-9 | 4 days | Kastelein Johannes Jacob PieterChief Scientific Officer | SSale | −300.0K | $30.30 | −$9.09M | −81.2%69.3K after | 3 lots10b5-1 |
Top 10 13F holders, Q2 2026
See all 194 holdersThe largest institutional positions in NewAmsterdam Pharma Co N.V. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 18,088,902 | $613.0M | 13.35% | +1,145,128+6.8% | Added |
| Capital World Investors | 12,230,557 | $414.5M | 0.05% | +1,121,523+10.1% | Added |
| FMR LLC | 10,339,663 | $350.4M | 0.02% | +1,573,852+18.0% | Added |
| Ra Capital Management, L.P. | 9,550,191 | $323.7M | 2.81% | 00.0% | Unchanged |
| FCPM III Services B.V. | 8,490,353 | $287.7M | 38.34% | −708,547−7.7% | Reduced |
| Deerfield Management Company, L.P. (Series C) | 4,264,789 | $144.5M | 1.51% | 00.0% | Unchanged |
| Viking Global Investors LPSuperinvestorViking Global Investors | 4,203,567 | $142.5M | 0.41% | 00.0% | Unchanged |
| Bain Capital Life Sciences Investors, LLC | 3,806,566 | $129.0M | 7.67% | −3,500,000−47.9% | Reduced |
| Maverick Capital LtdSuperinvestorMaverick Capital | 3,267,802 | $110.7M | 1.00% | +1,081,400+49.5% | Added |
| Duquesne Family Office LLCSuperinvestorDuquesne Family Office | 3,070,146 | $104.0M | 2.39% | 00.0% | Unchanged |
Holders of 5% or more of NAMS
See all 5 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of NewAmsterdam Pharma Co N.V..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Capital World Investors | 13G/A | 10.40%12.2M shares | +1.70 ppfrom 8.70% | May 13, 20254 filings | Jun 4, 2026 | SEC |
| FMR LLC | 13G/A | 10.00%11.9M shares | +1.20 ppfrom 8.80% | Feb 5, 20264 filings | Nov 5, 2026 | SEC |
| Ra Capital Management, L.P. | 13G/A | 9.90%11.1M shares | 0.00 ppfrom 9.90% | Dec 2, 20226 filings | May 15, 2025 | SEC |
| Frazier Life Sciences X, L.P. | 13D/A | 8.70%10.4M shares | +1.00 ppfrom 7.70% | Jun 9, 20237 filings | Sep 22, 2026 | SEC |
| Forbion Capital Fund IV Cooperatief U.A. | 13D/A | 8.30%9.32M shares | −1.10 ppfrom 9.40% | Jul 7, 20236 filings | Sep 30, 2025 | SEC |